Oct 23, 2026 · 9 min
SpaceX pressure rattles telecom stocks as Moderna’s good news disappoints
Deckers Outdoor Slides, T-Mobile Falls, and Moderna Drops
The episode shows how expectations, competitive threats, and strategic ambition can move markets even when underlying news looks positive.
- 1Deckers cut its sales outlook despite higher earnings guidance, partly reflecting a one-time tariff refund benefit.
- 2Reports of SpaceX pursuing roughly 80,000 cell sites pressured T-Mobile, Verizon, and other wireless stocks.
- 3Moderna shares fell after melanoma-vaccine data showed a 42% reduction in recurrence risk but arrived below investor expectations.
Don't miss
Moderna’s shares fall despite melanoma-vaccine results reporting a 42% reduction in cancer recurrence risk, because expectations were even higher.
The brief
The market’s movers reveal a recurring tension: strong results can still punish a stock when expectations run higher, while strategic threats can hit entire industries at once.
Deckers Outdoor fell after cutting its annual sales outlook, even as earnings guidance rose; a one-time tariff refund accounted for part of that improvement.
Reports that SpaceX may acquire roughly 80,000 U.S. cell sites sent T-Mobile, Verizon, and other wireless stocks lower by raising the prospect of a nationwide rival.
Moderna shares dropped despite melanoma-vaccine results showing a reported 42% reduction in recurrence risk, underscoring how investor expectations can overwhelm encouraging data.
The episode widens its lens to Elon Musk’s hiring culture at SpaceX, Dubai’s smart-city planning, and signs that U.S. electric-vehicle sales are regaining momentum.
The clearest lesson is that markets price the gap between reality and expectation: good news can disappoint, while ambitious expansion can unsettle established players.
Books & mentions
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.